Die psychedelische Verbindung Ibogaine kann die Gehirnaktivität verändern und die psychiatrischen Symptome bei Personen mit traumatischer Hirnverletzung verbessern. In einer Gruppe von Kampfveteranen war es mit Verbesserungen der kognitiven Funktionen, des posttraumatischen Stresses und der Angst verbunden.

I’ve linked to the news release in the post above. In this comment, for those interested, here’s the link to the peer reviewed journal article:

https://www.nature.com/articles/s44220-025-00463-x

From the linked article:

A new study published in Nature Mental Health provides initial evidence that the **psychedelic compound ibogaine may alter brain activity and improve psychiatric symptoms in individuals with a history of traumatic brain injury. In a group of combat veterans, researchers found that magnesium-ibogaine therapy was associated with changes in cortical oscillations and neural complexity, which were linked to improvements in cognitive functioning, post-traumatic stress, and anxiety**. These findings offer a rare look at the neural effects of ibogaine in humans and suggest that altered brain rhythms may play a role in its therapeutic potential.

Ibogaine is a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central Africa. Traditionally used in spiritual ceremonies, ibogaine has gained attention in recent years for its possible therapeutic properties, particularly in treating substance use disorders. More recently, anecdotal reports and small studies have suggested that it might help with symptoms related to traumatic brain injury, or TBI, such as anxiety, depression, cognitive dysfunction, and post-traumatic stress.

Unlike classic psychedelic compounds such as psilocybin or LSD, ibogaine is categorized as oneirogenic—it tends to produce immersive, dream-like states accompanied by extended periods of self-reflection. Its effects are long-lasting and pharmacologically complex. Ibogaine interacts with a wide array of targets in the brain, including serotonin and dopamine transporters, opioid receptors, and the N-methyl-D-aspartate system. Despite this pharmacological breadth, little is known about how ibogaine alters human brain function.